Scarica l'app Stockscreener
305.35
1.25%
-3.875
Dopo l'orario di chiusura:
305.35
0.005
+0.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$309.22
Aprire:
$308.02
Volume 24 ore:
583.47K
Relative Volume:
0.94
Capitalizzazione di mercato:
$13.77B
Reddito:
$2.99B
Utile/perdita netta:
$1.21B
Rapporto P/E:
12.18
EPS:
25.06
Flusso di cassa netto:
$1.13B
1 W Prestazione:
-0.37%
1M Prestazione:
+0.28%
6M Prestazione:
-5.65%
1 anno Prestazione:
-12.57%
Intervallo 1D:
$305.03
$312.44
Intervallo di 1 settimana:
$303.59
$315.73
Portata 52W:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Confronta UTHR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
305.35 | 13.98B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
155.37 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.86 | 46.99B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.71 | 43.17B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.05 | 20.82B | 16.70B | -157.13M | 1.19B | -0.155 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
Published on: 2025-08-27 13:41:12 - Newser
Using flow based indicators on United Therapeutics CorporationWeekly Loss Report & Weekly High Return Forecasts - Newser
How hedge fund analytics apply to United Therapeutics Corporation stockMarket Activity Report & Daily Profit Focused Screening - Newser
MannKind rises as United Therapeutics expands deal (MNKD) - Seeking Alpha
Leading vs lagging indicators on United Therapeutics Corporation performanceDollar Strength & Capital Efficiency Focused Ideas - Newser
MannKind Amends License Agreement with United Therapeutics - TipRanks
United Therapeutics expands partnership with MannKind for new therapy - Investing.com
MannKind expands collaboration with United Therapeutics, receives $5 million upfront - Investing.com
MannKind Corporation Collaborates with United Therapeutics to Develop Second Dry Powder Inhalation Therapy - Quiver Quantitative
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - uk.finance.yahoo.com
How to monitor United Therapeutics Corporation with trend dashboards2025 Fundamental Recap & Consistent Profit Alerts - Newser
United Therapeutics Corporation stock trend forecastTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser
Momentum divergence signals in United Therapeutics Corporation chartQuarterly Earnings Report & High Accuracy Trade Alerts - Newser
Published on: 2025-08-26 12:14:12 - Newser
What’s next for United Therapeutics Corporation stock priceBear Alert & Low Drawdown Momentum Trade Ideas - Newser
Published on: 2025-08-26 11:15:14 - Newser
How to build a dashboard for United Therapeutics Corporation stockInsider Buying & Expert Verified Stock Movement Alerts - Newser
Historical volatility pattern of United Therapeutics Corporation visualizedWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
Detecting price anomalies in United Therapeutics Corporation with AIWeekly Loss Report & Free Real-Time Market Sentiment Alerts - Newser
Published on: 2025-08-23 04:09:17 - Newser
Can United Therapeutics Corporation hit a new high this monthJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
United Therapeutics stock holds Buy rating at UBS on Tyvaso prospects - Investing.com Nigeria
Order flow analysis tools used on United Therapeutics Corporation2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser
Key resistance and support levels for United Therapeutics CorporationEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - MSN
United Therapeutics stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
United Therapeutics stock price target raised to $415 from $385 at UBS - Investing.com
United Therapeutics stock price target raised to $415 from $385 at UBS By Investing.com - Investing.com South Africa
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer - The Globe and Mail
Pfizer’s Inclacumab Study: Long-term Safety Insights for Sickle Cell Disease - The Globe and Mail
Should You Be Adding United Therapeutics (NASDAQ:UTHR) To Your Watchlist Today? - 富途牛牛
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks
MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool
H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey
United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest
United Therapeutics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks
United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Aug 21 '25 |
Sale |
308.75 |
11,000 |
3,396,249 |
36,781 |
0.94%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):